CV Sciences, Inc. (CVSI) Starts Presentation at NobleCon13
CV Sciences (OTC: CVSI) focuses on developing and commercializing novel therapeutics utilizing synthetic Cannabidiol (CBD). The company operates through two segments, Specialty Pharmaceutical and Consumer Product. It also manufactures, markets and sells plant-based CBD products under PlusCBD brand for a range of market sectors, including nutraceutical, beauty care, specialty foods and vape. The company’s Pharmaceutical Division is developing synthetically formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for treatment of…